Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
ITI-H4 CRISPR/Cas9 KO Plasmid (h): sc-403358
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- ITI-H4 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the ITI-H4 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: ITI-H4 Antibody (F-9): sc-515353
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ITI-H4 CRISPR/Cas9 KO Plasmid (h) | sc-403358 | 20 µg | $397.00 |
Overview
ITIH4 encodes inter-α-trypsin inhibitor heavy chain H4 (ITI-H4), a liver-enriched secreted glycoprotein that associates with the inter-α-inhibitor family and contributes to extracellular matrix organization and modulation of protease activity in the circulation. ITI-H4 is linked to inflammatory and acute-phase biology, with regulation influenced by cytokine-driven pathways that reshape plasma protein composition during tissue injury and immune responses. Altered ITIH4 expression and processing has been reported across multiple disease contexts, including inflammatory disorders and cancer-associated proteomic signatures, supporting its use as a mechanistic and biomarker-adjacent research target. As a soluble factor impacting extracellular milieu and cell–matrix interactions, ITIH4 is relevant for studying pathways governing inflammation, tissue remodeling, and microenvironmental regulation.
ITI-H4 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the ITIH4 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the ITIH4 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the ITIH4 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish ITI-H4 protein expression.
This CRISPR knockout system enables efficient generation of ITIH4-deficient cell models for investigation of ITI-H4 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting ITIH4 exon(s) critical for ITI-H4 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple ITIH4 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by ITI-H4 CRISPR/Cas9 KO Plasmid (h) and ITI-H4 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the ITIH4 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by ITI-H4 HDR Plasmid (h) and ITI-H4 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by ITIH4 homology arms to support homology-directed repair at defined ITIH4 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.